 BOSTON--BUSINESS WIRE--Gamida Cell Ltd. Nasdaq: GMDA, an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced the launch of a follow-on public offering of its ordinary shares. In addition, Gamida Cell expects to grant the underwriters a 30-day option to purchase up to an additional 15 of the ordinary shares to be sold in the offering on the same terms and conditions. The offering is subject to market and other conditions, and 